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PERSPECTIVES ON DRUGS 
Synthetic cannabinoids  
in Europe
Synthetic cannabinoids, or more correctly, synthetic 
cannabinoid receptor agonists, mimic the effects of cannabis 
and are the largest group of compounds monitored at 
European level by the EU Early Warning System on new 
psychoactive substances (EWS). ‘Legal high’ products 
containing synthetic cannabinoids have probably been 
sold as herbal smoking mixtures since at least 2006. These 
products do not necessarily contain tobacco or cannabis 
but when smoked, produce effects similar to those of 
cannabis. Recently, new liquid products containing synthetic 
cannabinoids have emerged for use with electronic cigarettes. 
They have been subject to innovative marketing approaches 
and are widely available on the Internet and in some shops in 
urban areas (often called ‘head’ or ‘smart’ shops).
The number of substances, their chemical diversity and the 
rate of their emergence makes this group of compounds 
particularly challenging in terms of detection and monitoring.
The common property of all synthetic cannabinoids is 
that they act upon the cannabinoid receptors in the body, 
mimicking to variable degrees the effects of ∆9-THC, the 
main active chemical found in cannabis. However, little is 
known about the pharmacology and toxicology of this group 
of substances in humans. It is possible that apart from high 
potency, some of these substances could have particularly 
long half-lives, potentially leading to a prolonged psychoactive 
effect. This analysis aims to provide an update on the current 
knowledge of these substances and their effects, as well as 
trends in production, availability and use. 
Synthetic cannabinoids represent the 
largest group of compounds currently 
monitored in Europe by the EU Early 
Warning System on new psychoactive 
substances. Current knowledge on 
these substances, as well as trends 
in production, availability and use, are 
presented in this analysis. 
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Full edition of this article with interactive  
features available online at
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I  The emergence of synthetic cannabinoids
It was not until 2008 that forensic investigators in Germany 
and Austria first detected the substance JWH-018, a synthetic 
cannabinoid, in Spice products. Subsequently several 
cannabinoids were detected in herbal smoking mixtures 
or so-called incense/room odorisers. Typical of these were 
Spice Gold, Spice Silver and Yucatan Fire, but many other 
products later appeared. Many of the cannabinoids that have 
subsequently been detected on the open market were first 
developed by scientists investigating the mode of action of 
cannabinoids on signalling pathways in the body, as well as 
their potential as therapeutic agents, such as analgesics. 
However, so far it has proved difficult to separate the desired 
therapeutic properties from unwanted psychoactive effects. 
The number of synthetic cannabinoids detected through the 
EWS continues to grow year on year. There were 9 reported 
in 2009, 11 in 2010, 23 in 2011, 30 in 2012, 29 in 2013 and 
30 in 2014 with a total of 134 synthetic cannabinoids having 
been notified to the EMCDDA as of December 2014. 
Synthetic cannabinoids play an important role in the rapidly 
evolving ‘legal highs’ market. ‘Legal highs’ is an umbrella 
term used to describe unregulated (new) psychoactive 
substances that are usually intended to mimic the effects of 
controlled drugs and sold on the open market. This is an area 
characterised by limited data on use, with the risks and harms 
largely unknown, and where high potency levels are of serious 
concern. There can be, for example, considerable inter-and 
intra-batch variability in ‘legal high’ products containing 
synthetic cannabinoids, both in terms of the substances 
present and their concentrations.
I  Manufacture of synthetic cannabinoid products
Most of the synthetic cannabinoid powders that are used in 
‘legal high’ products are manufactured in China and then are 
shipped in bulk using established legitimate transport and 
distribution networks. Multi-kilo shipments are frequently 
intercepted by authorities in Europe but the purity is rarely 
determined. One study from South Korea reported purities 
of between 75% and 90% for bulk powder samples. In 2013, 
over 21 000 seizures of synthetic cannabinoids were reported 
to the EWS amounting to more than 1.5 tonnes of material, 
of which almost 600 kilograms was bulk powder material, 
with China being a notable source country. Once in Europe, 
the retail products are put together. Damiana (Turnera 
diffusa) and lamiaceae herbs such as Mellissa, Mentha and 
Thymus are commonly used as the herbal base for the active 
synthetic chemical ingredients. The bulk chemicals are mixed 
with or sprayed onto the herbs, typically on an industrial scale 
often using equipment like cement mixers and liquid solvents 
such as acetone or methanol to dissolve the powders. Once 
mixed, the herbs are then dried and packaged for sale, either 
on the Internet by ‘legal high’ retailers or from certain shops in 
urban areas.
Due to the high potency of some synthetic cannabinoids,  
the amount of powder needed for each product unit can 
be in the order of a few tens of milligrams. Therefore, each 
kilogram of powder may be used to produce thousands of 
‘legal high’ products. Discovery of processing and packaging 
facilities and large quantities of synthetic cannabinoids in 
the Netherlands and Belgium suggest the involvement of 
organised crime in the distribution process. There is also 
evidence of a significant Internet retail trade within the 
European Union, with customs and police making regular 
seizures of small quantities of these products.
Systematic monitoring of online shops selling ‘legal high’ 
products provides some insight into the range of smoking 
and herbal mixtures available for purchase, many of which 
are likely to contain synthetic cannabinoids. Such monitoring, 
when combined with test purchasing of products for sale 
is also a way of both keeping track of how the substances 
contained in a product change over time, as well as helping 
in the early detection of new cannabinoids that appear on the 
market.
I  Prevalence
The extent to which synthetic cannabinoid products are 
used is largely unknown, however the situation is improving 
as more countries incorporate questions about use of new 
drugs into their general surveys. From the information that 
is currently available, it would appear that the prevalence of 
synthetic cannabinoids in the general population is very low. 
A number of surveys aimed at examining the prevalence of 
use of ‘Spice’-like products have been launched but their 
coverage and representativeness remains limited.
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There are notable differences between the prevalence of 
synthetic cannabinoids in the European and American drug 
markets. The most recent US prevalence data comes from 
the 2014 US Monitoring the Future survey of students, which 
suggests use is declining with last year prevalence for use of 
synthetic cannabinoids for 17/18 year olds of 5.8% in 2014, 
down from 7.9% in 2013 and 11.3% in 2012. A number of 
surveys in EU countries also report on the use of synthetic 
cannabinoids, although they are not comparable because 
of different methods, sampling frames and terminology. 
Overall, however, these individual studies indicate very low 
prevalence levels. The United Kingdom (England and Wales) 
asked about use of ‘Spice’ in two consecutive household 
surveys and reported lifetime prevalence levels for adults   
(16 to 64) at 0.2% in 2010/2011 and 0.1% in 2011/2012.  
The question was not repeated in subsequent years due to 
the low prevalence rate. In Spain, a 2012 national survey on 
drug use in students aged 14 to 18 years with a sample of 
27 503, also identified low levels of use of ‘Spice’ products 
with 1.4%, 1.0% and 0.6% reported for lifetime, last year and 
last month prevalence, respectively, a small increase from 
the previous survey results from 2010 (1.1%, 0.8% and 0.5% 
respectively). This compares with 0.5%, 0.1% and 0% in a 
more general Spanish survey of 15-64 year olds conducted 
in 2013. In France, in 2014, a global survey for adults (18 to 
64) with a question about use of “synthetic cannabinoids” 
reported an experimentation of 1.7 %. First time users of 
these new synthetic products are mostly men (2.3% vs. 
1.2% of women) and from the youngest generation (under 
35 years): 4.0% of 18-34 years old have tried synthetic 
cannabinoid against only 0.6% of 35-64 (Baromètre Santé). 
Another survey in France, for young people aged 17, reported 
that 1.7 % of them have already used a synthetic cannabinoid 
(ESCAPAD). In Germany, the city of Frankfurt has studied the 
use of herbal mixtures and ‘Spice’ among students aged 15 
to 18 years. They reported lifetime levels of use at 7% in 2009, 
9% in 2010, 7% in 2011 and 7% in 2012. In 2013, lifetime 
use of herbal mixtures dropped to 5%. Students reporting the 
consumption of ‘Spice’ were, for the most part, experienced 
cannabis consumers. Finally, a number of studies among 
particular groups (clubbers, Internet users, etc.) with non-
probabilistic samples have generally identified higher levels 
of synthetic cannabinoid use than among the general 
population. The 2012 Global Drug Survey, for example, 
reported last year prevalence levels of 3.3% among all UK 
respondents (not representative of the general population) 
and 5.0% among UK regular clubbers.
I  Adverse health consequences associated with 
synthetic cannabinoids
The adverse health effects associated with synthetic 
cannabinoids are linked to both the intrinsic properties of 
the substances and to the way the products are produced. 
There have been numerous reports of non-fatal intoxications 
and a smaller number of deaths associated with their use. 
As some of these compounds are very potent, the potential 
for toxic effects is high. This may be compounded by the 
manufacturing process which can lead to the uneven 
distribution of the substances within the herbal material, 
which may result in some products containing doses that are 
higher than intended.
There have been several notable outbreaks of serious 
acute intoxications linked to legal high products containing 
synthetic cannabinoids in countries outside the EU. It is 
of concern that the cannabinoids in question have also 
often been seized in the EU, leading the EU Early Warning 
System to issue public health alerts to its network across 
I  Facts and figures 
101 new psychoactive substances were reported to 
EMCDDA in 2014, 30 were synthetic cannabinoids
137 synthetic cannabinoids in total being monitored by EU 
Early Warning System (February 2015)
14 recognisable chemical families of synthetic cannabinoids 
are known
2008 — a synthetic cannabinoid, JWH-018, first detected 
in Spice products
Interactive: demystifying the chemistry available on the EMCDDA website:  
emcdda.europa.eu/topics/pods/synthetic-cannabinoids
I  Interactive element
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Europe. During 2013, five deaths associated with the use 
of 5F-PB-22 were reported in the United States. In 2014, 
an outbreak of non-fatal intoxications occurred in Colorado, 
United States associated with ADB-PINACA. While towards 
the end of 2014, media outlets in Russia reported two large 
outbreaks of adverse events associated with the smoking of 
a ‘legal designer drug’ or ‘Spice’, most probably a synthetic 
cannabinoid.
The reported adverse effects of synthetic cannabinoid 
products include agitation, vomiting, drowsiness and 
confusion. Although some of these are similar to symptoms 
observed after a high dose of cannabis, researchers have 
suggested that products containing synthetic cannabinoids 
are potentially more harmful than cannabis. Some of the 
more serious effects include kidney damage, pulmonary 
and cardiovascular effects and convulsions. A case report 
published in 2013 associated the use of JWH-018 with 
acute ischemic strokes in two otherwise healthy males. In 
addition, there is some evidence to suggest that synthetic 
cannabinoids can be associated with psychiatric symptoms, 
including psychosis. It is probable that some of the adverse 
effects are due to mechanisms other than interaction with 
the cannabinoid receptors, for example, the inhibition of 
monoamine oxidase.
From the monitoring of such adverse events by the EU Early 
Warning System and from our current knowledge of the 
physiological and toxicological effects of selected synthetic 
cannabinoids, it is clear that these compounds carry the 
potential to cause harm to human health, although the 
mechanisms of how this happens are poorly understood at 
present.
I  Recent developments
Since the beginning of the synthetic cannabinoid 
phenomenon, these substances were largely detected in 
products sold as ‘herbal smoking mixtures’. More recently, 
however, several countries have also reported finding the 
substances in products that look like cannabis resin either 
in branded ‘legal high’ products such as ‘Afghan Insense’ 
or simply masquerading as cannabis resin on the illicit 
market. This development is likely to be a response to the 
popularity of cannabis resin in many countries. Synthetic 
cannabinoids have also been detected in mixtures containing 
other new psychoactive substances such as stimulants, 
hallucinogens and sedative/hypnotics. This may be deliberate 
or accidental. In a small number of cases, the presence of 
synthetic cannabinoids has been detected in what appear 
to be ecstasy tablets. Another recent development has been 
the discovery of synthetic cannabinoids in the liquid-filled 
cartridges for use in electronic cigarettes. This most likely 
reflects the recent popularity of ‘vaping’ among young people.
The EMCDDA EWS has been closely monitoring developments 
among synthetic cannabinoids since their arrival on the 
European market in 2008. A striking feature has been the way 
in which this chemical family has evolved and adapted during 
this time. It is clear that the innovative chemical substitution 
patterns which have characterised this phenomenon, mean 
that close surveillance of new developments in the field, as 
well as of synthetic cannabinoid-related harms, will remain 
paramount in the future.
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Many of the compounds monitored by the EWS have code 
names that relate to their discovery. In some cases they 
are derived from the initials of the name of the scientists 
that first synthesised them: e.g. ‘JWH’ compounds after 
John W. Huffman and ‘AM’ compounds after Alexandros 
Makriyannis. In other cases they may originate from the 
institution or company where they were first synthesised: 
the ‘HU’ series of synthetic cannabinoids being from the 
Hebrew University in Jerusalem, or ‘CP’ for Carl Pfizer. In 
some cases, names have probably been chosen to help 
market the products. Striking examples of this are ‘AKB-
48’ and ‘2NE1’, alternative names used for APINACA and 
APICA. ‘AKB-48’ is the name of a popular Japanese girl 
band and ‘2NE1’ is the name of a girl band from South 
Korea. Finally, the synthetic cannabinoid, XLR-11, appears 
to have been named after the first liquid fuel rocket 
developed in the USA for use in aircraft, perhaps alluding 
to the vendor’s intention for those who consume the 
substance.  
 
Many substances are now given code names that are 
derived from their long chemical names such as: APICA 
from N-(1-adamantyl)-1-pentyl-1H-indole- 3-carboxamide 
and APINACA from N-(1-adamantyl)-1-pentyl-1H-indazole-
3-carboxamide. The EMCDDA has systematised this 
method in order to apply it to newly emerging substances 
and show how the various constituent parts can be put 
together. The structures of many synthetic cannabinoids 
can be categorised into 4 components: tail, core, linker 
and linked group. Assigning each component a codename 
allows the chemical structure of the cannabinoid to be 
identified without the long chemical name. The proposed 
naming syntax for the synthetic cannabinoids that follow 
this pattern is as follows: 
 
LinkedGroup – TailCoreLinker
Ordering the components in this manor follows the ordering 
as seen in their longer chemical names, as with APICA: 
N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide. When 
a tail substituent is present (i.e. 5F), this will be displayed 
at the front of the name and linked group substituents will 
be placed before the linked group; core substituents will be 
placed at the end of the code. 
 
Applying the new system to a recently notified synthetic 
cannabinoid: 
 
 
 
 
 
 
 
 
 
 
N-(1-carbamoyl-2-methyl-propyl)-1-[(4-fluorophenyl)methyl]
indazole-3-carboxamide 
 
Current name: AB-FUBINACA       
New name: MABO-FUBINACA 
 
The letter codes used are based not only on the letters used 
but the ordering of letters. For example, A identifies the 
amine in the linked group. CA identifies the carboxamide. 
By following the syntax and codes described, synthetic 
cannabinoids that follow this structure will have a unique 
short name. 
 
Visit the POD website for more information:  
www.emcdda.europa.eu/topics/pods/synthetic-
cannabinoids
Chemistry and naming of the synthetic cannabinoids  
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